We attempted the concept of engaging genomic information to stratify individuals for CHF prognostic risk and to improve risk reclassification for participants, and we demonstrated a hypothesis to predict the outcomes of genomic screening to complement conventional risk and NT‐proBNP. This evidence concerns the gene NPPB and congestive heart failure.